CSF biomarkers of neurotoxicity in childhood cancer survivors after cranial radiotherapy or surgery
Annals of Clinical and Translational Neurology · 2024
DOI: 10.1002/acn3.52152 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, 2024. Verfasst von Erik Fernström und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Sahlgrenska University Hospital, Gothenb…. Hauptthemen laut MEDLINE: Cancer Survivors, Medulloblastoma, Biomarkers. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alzheimer Drug Discovery Foundation (ADDF), USA, Hjärnfonden, Sweden, European Union Horizon Europe Research and Innovation Programme.
Abstract (Originalsprache)
Objective
Treatment of pediatric brain tumors is associated with potential long‐term cognitive sequelae. Patients treated with craniospinal irradiation for posterior fossa tumors are at high risk. New biomarkers that could help to differentiate treatment effects from other causes of cognitive dysfunction would be valuable in tailoring optimal survivorship care. Biomarkers that reflect biological mechanisms behind treatment‐associated cognitive decline would also be important in the evaluation of future treatment regimens for pediatric brain or skull base tumors.
Methods
In this biomarker‐finding study, 10 adult survivors of pediatric medulloblastoma, skull base tumors, and posterior fossa low‐grade glioma underwent study specific lumbar puncture at a minimum of 17 years following treatment. We analyzed cerebrospinal fluid biomarkers reflecting neuron and astrocyte integrity, amyloid metabolism, inflammation, extracellular matrix, synaptic integrity, and blood–brain barrier function. The values were compared with biomarker levels in healthy controls of comparable age.
Results
Biomarkers reflecting neuronal injury (neurofilament light chain protein), astrocyte injury or activation (glial fibrillary acidic protein) as well as inflammation (YKL‐40) were significantly elevated in cancer survivors compared to controls. Biomarkers reflecting amyloid metabolism showed a pattern of decrease in patients treated for medulloblastoma.
Interpretation
The results suggest a potential chronic low‐grade neurodegeneration and astrocyte activation in patients treated for pediatric brain or skull base tumors. Protein biomarkers of CNS disease could potentially be used to increase our understanding of the contribution from different tumor treatments with regard to long‐term symptoms in cancer patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden.
- Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
- Department of Clinical Neuroscience, Institute of Neuroscience and Physiology at the Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
- Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
- Regional Cancer Centre West, Western Sweden Healthcare Region, Gothenburg, Sweden.
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
ORCID-Profile: Erik Fernström
Förderung
- Alzheimer Drug Discovery Foundation (ADDF), USA
- Hjärnfonden, Sweden
- European Union Horizon Europe Research and Innovation Programme
- EU Joint Programme - Neurodegenerative Disease Research
- UK Dementia Research Institute at UCL
- Swedish Research Council
- European Union Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement (MIRIADE)
- Swedish State under the ALF-Agreement
Zitieren
APA
Fernström, E., Jarfelt, M., Blomstrand, M., Lannering, B., Axelsson, M., Wasling, P., Björk-Eriksson, T., Zetterberg, H., & Kalm, M. (2024). CSF biomarkers of neurotoxicity in childhood cancer survivors after cranial radiotherapy or surgery. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.52152
Vancouver
Fernström E, Jarfelt M, Blomstrand M, Lannering B, Axelsson M, Wasling P, et al. CSF biomarkers of neurotoxicity in childhood cancer survivors after cranial radiotherapy or surgery. Annals of Clinical and Translational Neurology. 2024. doi:10.1002/acn3.52152
BibTeX
@article{Fernstrm2024,
author = {Fernström, Erik and Jarfelt, Marianne and Blomstrand, Malin and Lannering, Birgitta and Axelsson, Markus and Wasling, Pontus and Björk-Eriksson, Thomas and Zetterberg, Henrik and Kalm, Marie},
title = {CSF biomarkers of neurotoxicity in childhood cancer survivors after cranial radiotherapy or surgery},
journal = {Annals of Clinical and Translational Neurology},
year = {2024},
doi = {10.1002/acn3.52152}
}
EUVIMED